Agenda for Day 1 - Monday 9 November, 2026Monday, 9 November 2026

Location: Regulatory Strategy Stage

Interactive Workshop

For a company at early or later-stage development considering commercialisation, few decisions carry more lasting impact than how to enter the market: partnering or licensing with an established regional player, building a commercial organization and launching independently, or some combination of the two.

Each path changes the value the company ultimately captures, the capital it must commit, the risk it absorbs, and the organization it becomes.

This panel brings together senior biopharma leaders who chose differing strategic pathways across regions. They will share why each company took the route it did, how the alternatives were weighed against value creation, strategic feasibility, and financial constraints, and how each arrived at the right go-to-market strategy for the region.

Panelists will speak candidly about the lessons they learned, their key success factors, and the things they might have done differently alongside key considerations for companies at an early stage of decisioning.

Location: Biomanufacturing Strategy Stage

Interactive Workshop

For most global biotechs, the hardest part of entering Japan is not regulation — it is finding the right clinical leader. Sponsors typically begin by selecting a CRO, but the decisive first move is identifying the Japanese Principal Investigator best suited to the asset: the physician who understands the disease, can reach the target patients, and is willing to lead a registration-directed program.

This workshop presents a PI-led alternative to the traditional sponsor-and-CRO model. Drawing on a national PI network coordinated through an Osaka hub, we show how asset assessment, Japan-specific evidence-gap analysis, early PMDA consultation, and a registration-directed investigator-initiated trial (IIRDT) can be combined into a single pathway — one that may, for serious diseases with high unmet need, support a conditional approval strategy in Japan.

We will also cover where AI genuinely helps (PI matching, protocol design, patient screening, DCT orchestration) and where it must not: AI assists, the PI decides, and GCP accountability stays with the investigator. Recent Japanese proof points will be shared, including a program in which 11 participating PIs produced 30 grant applications and six secured public grants totalling JPY 315M within three months.

Key takeaways:

1. Why the real entry barrier into Japan is the absence of the right clinical leader — and how Doctor-to-Doctor peer referral identifies that PI

2. How to choose between a Japan-focused IIRDT and an MRCT based on asset characteristics: MRCT is an option, not the default

3. What a conditional approval strategy realistically requires in Japan — including the post-marketing obligations that come with it

4. Where AI and decentralized trial design add speed and patient reach, and the governance boundaries that keep a program PI-driven rather than PI-dependent

Location: Industry Voices Stage

Interactive Workshop

This panel will explore what truly drives success in Business Development and how aspiring BD professionals can build a rewarding and impactful career. Drawing on the experiences of seasoned dealmakers from both the buy-side and sell-side, the discussion will go beyond traditional career advice to examine the skills, experiences, relationships, and mindsets that matter most. From developing scientific, financial, and transactional expertise to building influence, credibility, and a strong professional network, panelists will share practical lessons learned throughout their careers. Attendees will gain actionable insights into navigating the BD profession, accelerating their development, and understanding what really moves the needle in a highly competitive industry.

Location: Ecosystem Innovation Stage

Interactive Workshop

Great corporate communicators shape perceptions, win attention and inspire action. This dynamic, practical session explores how to build a distinctive personal brand, craft stories that stick and turn presentations into powerful tools of persuasion. Participants will learn how to create compelling narratives, simplify complex messages, use anecdotes and visuals for maximum impact, and command attention from the first moment to the last. It will also show how to extend influence beyond the room through video, thought leadership, multichannel visibility and credible third-party endorsement. Delegates will leave with practical techniques to communicate with confidence, strengthen their profile and move people to think, feel and act differently.

Location: The Big Picture Stage

Europe possesses world-class science, but continues to lose talent, capital, and value to more competitive ecosystems abroad. What can be done to change this?

• This panel will bring together senior investors and members of the newly created European Life Sciences Coalition (ELSC), alongside biotech CEOs, around a shared goal: to found, fund, scale and retain Europe’s next generation of Life Sciences champions

• The session will open with a brief introduction to the ELSC and its objectives, followed by a call to action inviting participants to support an Open Letter to European leaders by adding their organisation’s logo

• Panellists will explore how to strengthen European biotech as an integrated ecosystem built around innovation, company creation, and well-functioning capital markets

• Moving beyond a diagnosis of the challenges, the discussion will focus on concrete, data-driven solutions around three objectives: mobilising institutional capital into European Life Sciences; accelerating the regulatory pathway from science to patients; and building deeper, more integrated European public capital markets for growth companies

• The interactive session will examine the full investment “food chain”, from company creation and venture funding through scale-up and public markets, and the policy reforms needed to keep innovation, talent, and capital in Europe, including through the EU Biotech Act

Location: Therapeutic Insights Stage

Powered by leading analyst intelligence and data-driven insights, this session offers a comprehensive exploration of the evolving therapeutic landscape. Dive into emerging trends, market dynamics, and investment opportunities across key therapeutic areas, and uncover how shifting R&D pipelines, regulatory changes, scientific breakthroughs, and technological advancements are transforming the biopharma industry. Gain a forward-looking perspective on the most promising therapeutic areas and high-growth investment opportunities, equipping you with the strategic insights needed to navigate 2026 and beyond.

Location: Therapeutic Insights Stage

Antibody-drug conjugates (ADCs) are transforming cancer treatment by delivering targeted therapy with precision, and as clinical data matures, they are attracting significant investment and partnership activity across the oncology landscape. This session examines the latest evidence on efficacy and safety, explores what the data reveals about how ADCs are reshaping treatment strategies across tumour types, and discusses which platforms and targets are capturing attention from investors and partners. With deal flow accelerating and new opportunities emerging, the session provides strategic considerations for evaluating partnerships and investments in this high-value oncology segment.

Location: Therapeutic Insights Stage

Oncology remains the largest and most competitive area of biotech innovation, but the path to success is becoming increasingly complex. Emerging modalities such as radioligand therapies, next-generation immunotherapies, cell therapies and precision-targeted approaches are generating significant excitement, yet investors and pharmaceutical companies are becoming more selective in how they evaluate risk, differentiation and commercial potential.

This panel brings together biotech innovators, pharma leaders and investors to discuss which oncology platforms are attracting the strongest scientific, partnering and investment interest, what makes a company stand out in a crowded landscape, and how capital, partnerships and clinical strategy can accelerate value creation. The discussion will explore where the next major opportunities in oncology may emerge and what will separate future winners from the rest of the field.

• Are radioligands becoming the next oncology platform?

• Can immunotherapy continue to generate venture-scale returns?

• Is precision medicine becoming too fragmented?

• What separates fundable oncology companies from unfundable?

Location: Therapeutic Insights Stage

Cell and gene therapies are redefining treatment possibilities across multiple diseases, and despite market challenges, they continue to command substantial investment and strategic interest. This session provides essential insights into the current landscape, highlights key developments across platforms and indications, and examines what recent clinical and commercial data reveal about the sector's trajectory. With deal dynamics evolving and new modalities emerging, the session explores funding trends, partnership strategies, and what key stakeholders need to know to navigate opportunities in this transformative field.

Location: Ecosystem Innovation Stage

The traditional boundaries of drug discovery are dissolving. Increasingly, pharmaceutical companies are opening their compound libraries, data, and expertise to the global research community through open innovation platforms. Initiatives such as opnMe from Boehringer Ingelheim are reshaping how early scientific ideas move from academia and biotech into the pharmaceutical pipeline. In this Ecosystem Innovation session at BIO-Europe, leaders from pharma, biotech, and venture capital will explore how open collaboration models are accelerating discovery, de-risking early research, and creating new pathways for partnership. From accessing pharma compounds to co-developing breakthrough therapies, the panel will examine how these platforms are changing the rules of engagement across the life sciences ecosystem. Join this conversation to understand what open innovation means for the next generation of biotech founders, academic innovators, and investors—and how collaboration across sectors is shaping the future of drug discovery.

Location: Ecosystem Innovation Stage

Canada is home to a dynamic life sciences ecosystem, combining world-class research, innovative companies, strong healthcare institutions, and growing biomanufacturing capabilities. This panel will provide an overview of Canada’s life sciences sector and feature selected Canadian companies that are developing cutting-edge technologies and solutions to address global healthcare challenges. Join us to learn about innovation trends, partnership opportunities, and the strengths that make Canada a leading life sciences hub.

Location: Ecosystem Innovation Stage

Despite remarkable advances in biomedical research, many promising discoveries never reach patients. Translating scientific innovation into therapies, diagnostics, and successful ventures remains one of the greatest challenges in healthcare innovation.

This fireside chat brings together Stefanie Dimmeler, spokesperson of the German Centers for Health Research (DZG), and a Heiko Lickert, founder of Viacure GmbH, who has successfully navigated the path from academic discovery to company creation. Together, they will share insights from Germany’s coordinated research model and discuss how collaborative networks can help accelerate translation, foster entrepreneurship, and create opportunities for industry partnership.

Drawing on real-world experiences, the conversation will explore the factors that enable successful translation, the barriers that continue to impede progress, and the lessons learned from building bridges between academia, healthcare, investors, and industry. The speakers will also reflect on how research ecosystems can evolve to better support innovation and deliver tangible impact for patients.

Offering both strategic and entrepreneurial perspectives, the session will provide valuable insights for biotech companies, investors, researchers, and partnering professionals interested in turning scientific excellence into real-world healthcare solutions.

Location: Ecosystem Innovation Stage

Through their EMEA Advance Biotech Grant Program, Merck recognize standout emerging biotech companies and helps them navigate their path to commercialization. Delivered as a dynamic competition, five selected biotech companies will have the opportunity to pitch their breakthroughs to Merck's Grant representatives and the overall BIO-Europe audience.

Finalists:

Conveyxo

Procavea Biotech

Luna Therapeutics

Nagene

Navira Bio

Location: Ecosystem Innovation Stage

Around the world, governments, investors, and industry leaders are racing to build the next great biotech hubs. From Boston and Basel to emerging ecosystems across Europe, Asia, and the Middle East, success depends on more than funding alone. Talent, infrastructure, translational science, and access to global pharma partners all play critical roles. Following a spotlight on emerging regional innovators, this panel at BIO-Europe brings together ecosystem builders from venture capital and pharma to research institutes and policy leaders to explore what it really takes to build a thriving life sciences cluster. What ingredients attract breakthrough startups? How can regions compete for talent and capital? And how can global collaboration ensure that innovation ecosystems remain connected rather than siloed? Join this discussion to understand how the next generation of biotech hubs will emerge and what it means for investors, startups, and partners worldwide.

Location: Seated Lunch Area

Led by subject matter experts sharing the latest thinking, Community Conversations, delivered through a dynamic roundtable format, provide a unique opportunity to gain cutting-edge insights while fostering meaningful peer exchanges, sharing best practices, and expanding your professional network.  

Choose between:

Crafting Your Regulatory Strategy to Align with Evolving Regulatory Frameworks 
Regulatory pathways are evolving rapidly, with greater emphasis on early engagement, adaptive approaches and evidence generation across the product lifecycle. Companies that understand how to align regulatory, clinical, manufacturing and commercial strategies early will be better positioned to accelerate development, reduce risk and maximise the value of innovation. Explore how emerging regulatory frameworks are changing the route to approval, how companies can use early scientific advice and collaborative approaches to shape development strategies, and what lessons can be learned from examples of successful regulatory navigation.

Led by: Raun Kupiec, Founder & Principal, R Kupiec Consulting

From Clinical Development to Commercial Success: Integrating Global Market Access into Trial Strategy 
Examine how aligning endpoints with payer needs across diverse markets can enhance trial outcomes. Consider strategies for selecting sites that balance speed, cost, and market positioning while addressing geopolitical risks in global trials. How can organisations build robust infrastructure in emerging markets to ensure seamless integration of global market access into their trial strategies? 

Led by: Mark Reid, Founder & Managing Director, Graythan Regulatory Services

Future-Proofing Your Biomanufacturing Strategy: Integrating Manufacturing From Day One 
Consider how embedding manufacturing considerations early can accelerate commercialisation and challenge traditional downstream approaches. What strategies can organisations adopt to build scalable, competitive therapies right from the start and stay ahead in an evolving biomanufacturing landscape? 

Led by: Dan Stanton, Trade Media Relations Expert, Sartorius and Stuart Tindal, Principal Platform Manager, Sartorius

Commercialisation and Global Launch: How Do You Build a Global Commercial Success?

Commercial success no longer depends on winning the US market alone. As biotech companies increasingly prepare for launches across multiple regions, the companies that succeed globally are those that build commercial strategy early, understand local market dynamics and create the right capabilities beyond their home market. Explore what companies should do differently when preparing for international launches, how early commercial planning should begin, and the common mistakes that can limit success. Examine the strategies that have enabled biotech companies to successfully build global franchises and maximise the value of their innovations worldwide.

Led by: Dave Thomas, Senior Advisor, Venture Valuation

Attracting and Retaining Top Talent in European Biotech 
If this keeps you awake at night and as a founder, entrepreneur, C-suite officer or HR professional – let’s discuss: strategies for building a competitive workforce to lead on a global scale while addressing skill gaps through targeted training initiatives. How can fostering diversity drive innovation, and what approaches can organisations adopt to retain top talent by offering career growth opportunities and workplace flexibility? How can this become part of your success story from start-up to scale up and exit or long-term growth?

Led by: Tony Jones, CEO of One Nucleus and Oliver Schacht, Managing Director, Life Science Nord

New Models for Biotech Partnerships: Adapting to Complexity and Capital Constraints 
How are partnering strategies changing in a world of constrained capital, global competition, and increasing scientific complexity? Discover how early licensing agreements can share risks and accelerate innovation, while co-development models combine resources and expertise. Explore the potential of venture creation to drive new opportunities and examine how pharma-biotech collaborations and academic partnerships can address complex scientific challenges. 

Executing your Deal: The Power of Alliance Management

Signing your deal is just the start. True value lies in how, and how quickly, partnerships advance your mutual project or product. Let’s discuss key traits of your high-performing collaborations, strategies for alignment, fostering collaboration, planning ahead, managing conflicts…., and explore how Alliance Management adapts to the additional complexity of digital-data-driven collaborations.

Led by: Anthony and Adrien Hörning, Partners, Strategic Transactions Advisory AG

Location: Seated Lunch Area

The roundtable Community Conversations will repeat in two blocks to allow attendees to move between sessions

Choose between:

Crafting Your Regulatory Strategy to Align with Evolving Regulatory Frameworks 
Regulatory pathways are evolving rapidly, with greater emphasis on early engagement, adaptive approaches and evidence generation across the product lifecycle. Companies that understand how to align regulatory, clinical, manufacturing and commercial strategies early will be better positioned to accelerate development, reduce risk and maximise the value of innovation. Explore how emerging regulatory frameworks are changing the route to approval, how companies can use early scientific advice and collaborative approaches to shape development strategies, and what lessons can be learned from examples of successful regulatory navigation.

Led by: Raun Kupiec, Founder & Principal, R Kupiec Consulting

From Clinical Development to Commercial Success: Integrating Global Market Access into Trial Strategy 
Examine how aligning endpoints with payer needs across diverse markets can enhance trial outcomes. Consider strategies for selecting sites that balance speed, cost, and market positioning while addressing geopolitical risks in global trials. How can organisations build robust infrastructure in emerging markets to ensure seamless integration of global market access into their trial strategies? 

Led by: Mark Reid, Founder & Managing Director, Graythan Regulatory Services

Future-Proofing Your Biomanufacturing Strategy: Integrating Manufacturing From Day One 
Consider how embedding manufacturing considerations early can accelerate commercialisation and challenge traditional downstream approaches. What strategies can organisations adopt to build scalable, competitive therapies right from the start and stay ahead in an evolving biomanufacturing landscape? 

Led by: Dan Stanton, Trade Media Relations Expert, Sartorius and Stuart Tindal, Principal Platform Manager, Sartorius

Commercialisation and Global Launch: How Do You Build a Global Commercial Success?

Commercial success no longer depends on winning the US market alone. As biotech companies increasingly prepare for launches across multiple regions, the companies that succeed globally are those that build commercial strategy early, understand local market dynamics and create the right capabilities beyond their home market. Explore what companies should do differently when preparing for international launches, how early commercial planning should begin, and the common mistakes that can limit success. Examine the strategies that have enabled biotech companies to successfully build global franchises and maximise the value of their innovations worldwide.

Led by: Dave Thomas, Senior Advisor, Venture Valuation

Attracting and Retaining Top Talent in European Biotech 
If this keeps you awake at night and as a founder, entrepreneur, C-suite officer or HR professional – let’s discuss: strategies for building a competitive workforce to lead on a global scale while addressing skill gaps through targeted training initiatives. How can fostering diversity drive innovation, and what approaches can organisations adopt to retain top talent by offering career growth opportunities and workplace flexibility? How can this become part of your success story from start-up to scale up and exit or long-term growth?

Led by: Tony Jones, CEO of One Nucleus and Oliver Schacht, Managing Director, Life Science Nord

New Models for Biotech Partnerships: Adapting to Complexity and Capital Constraints 
How are partnering strategies changing in a world of constrained capital, global competition, and increasing scientific complexity? Discover how early licensing agreements can share risks and accelerate innovation, while co-development models combine resources and expertise. Explore the potential of venture creation to drive new opportunities and examine how pharma-biotech collaborations and academic partnerships can address complex scientific challenges. 

Executing your Deal: The Power of Alliance Management

Signing your deal is just the start. True value lies in how, and how quickly, partnerships advance your mutual project or product. Let’s discuss key traits of your high-performing collaborations, strategies for alignment, fostering collaboration, planning ahead, managing conflicts…., and explore how Alliance Management adapts to the additional complexity of digital-data-driven collaborations.

Led by: Anthony and Adrien Hörning, Partners, Strategic Transactions Advisory AG

Blue Earth Therapeutics is a clinical-stage radiopharmaceutical company advancing the next generation of targeted radiopharmaceutical therapies with the aim of transforming the treatment of cancer.

Our mission is to develop radiopharmaceutical therapies that result in improved patient outcomes by delivering high radiation doses to tumours, without compromising on normal organ safety.

Founded in 2021 as a subsidiary of Bracco Imaging, the company was then partly spun out with Series A financing in 2024. Blue Earth Therapeutics unites a UK/US-based team with deep expertise across radiopharmaceutical development, oncology, and operations. Our leadership has proven track records in bringing innovative radiopharmaceuticals from concept to clinic.

With a strong foundation of proven leadership, scientific innovation, and strategic partnerships, Blue Earth Therapeutics is shaping the future of precision radiopharmaceutical therapies. Our initial focus is on prostate cancer, where we are advancing a pipeline of PSMA-targeted radiohybrid assets. Blue Earth Therapeutics operates through a reliable supply chain, leveraging a trusted network of external partners to ensure consistent manufacturing.

Bold Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel metallotherapeutic cancer therapies to address high unmet medical needs. The company's lead asset, BOLD-100, is a first-in-class ruthenium-based metallotherapeutic small molecule currently in Phase 2 clinical trials for advanced gastrointestinal cancers. BOLD-100 selectively targets GRP78, a key regulator of the Unfolded Protein Response leading to cellular apoptosis. In Phase 2 studies, BOLD-100 combined with standard of care FOLFOX therapy has demonstrated exceptional efficacy alongside an excellent safety profile in heavily pretreated GI cancer patients. Crucially, clinical data reveal a significant secondary attribute: marked protection against oxaliplatin-induced peripheral neuropathy. This dual product profile-improved progression free survival and overall survival paired with neuroprotection leads to improved clinical benefit while preserving patient quality of life. Bold Therapeutics is led by a management team with decades of collective experience in biopharmaceutical leadership, clinical trial execution, and regulatory strategy. As BOLD-100 advances toward pivotal trials, Bold Therapeutics is actively seeking global licensing, co-development, and investment partners to accelerate development and unlock the full commercial value of this first-in-class platform.

Ymmunobio is a preclinical-stage oncology company advancing a first-in-class ADC treatment solution based on the proprietary tumor specific antigen (TSA) NPTXR, a neo-expressed membrane protein found exclusively on cancer cells. The company's lead asset, YB-811, a dual payload Antibody Drug Conjugate (ADC), is designed to selectively target NPTXR-positive tumors with no off-tumor toxicity risk, leveraging third-generation linker-payload chemistry for superior safety and efficacy.

Ymmunobio's tumor marker shows extraordinarily high prevalence (57-98%) in more than a dozen of the most common and lethal cancers, enabling unmatched market breadth. The company holds exclusive global IP and intends to complete human proof-of-concept by 2028.

FoRx Therapeutics is a clinical-stage company that develops next-generation small molecule therapeutics targeting DNA Replication Stress pathways for anti-cancer therapy. The company is based in Basel, Switzerland, and structured as a lean organization with 10 employees and an integrated network of external partners.

FoRx's pipeline comprises differentiated, best-in-class as well as novel, first-in-class programs for oncology indications. The company's lead program is a highly potent and selective PARG inhibitor, FORX-428. Preclinically, the compound has shown strong evidence for best-in-class potential, having demonstrated excellent tolerability and greatly superior anti-tumor efficacy in multiple in vivo tumor models vs. competition. In the clinic, FORX-428 is being evaluated in an open-label study, initially taking place in the United States, to assess safety, tolerability, pharmacokinetics, as well as preliminary efficacy in patients with advanced solid tumors who have exhausted standard-of-care options. An initial data readout from the clinical trial is expected by the end of 2026.

FoRx Therapeutics has raised a total of CHF 70M so far and is backed by a syndicate of investors that include EQT Life Sciences, Novartis Venture Fund, Pfizer Ventures, and M Ventures.

Greenwich LifeSciences (Nasdaq: GLSI) is a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01 (NCT05232916), which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. Flamingo-01 has opened up to 160 sites in the US and Europe. Flamingo-01 is designed to evaluate the safety and efficacy of GLSI-100 in HER2/neu positive patients with residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients are planned to be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types are planned to be treated with GLSI-100 in a third arm. More than 1,300 patients have been screened with a current screen rate of approximately 800 patients per year. The 250 patient non-HLA-A*02 arm is now fully enrolled, where all patients received GLSI-100 and immune response data from this arm has been recently presented at AACR and ASCO in 2026.

MEDiC Life Sciences is a clinical stage company leveraging millions of artificial biomarker combinations to advance novel cancer precision medicines with matched synthetic lethal biomarkers. We can rely on a growing proprietary data source of more than 1000 genome-wide CRISPR screens leveraging 3D cancer models and are advancing our lead asset, SLS-01, into a Phase 1B clinical trial in Q4 2026.

To drive continued growth of our pipeline, we are launching the BEACON project, a collaboration with multiple biopharma companies to explore a "second life" for de-prioritized assets. By testing these assets across a large-scale library of biomarker combinations, we aim to identify novel clinical development strategies. We are actively pursuing in-licensing opportunities and NewCo formation.

Pin Therapeutics is a clinical stage TPD (Targeted Protein Degradation) company dedicated to developing novel E3 ligases and molecular glue degraders for the treatment of solid tumors and hematologic cancers. Our lead program, PIN-5018, a first-in-class CK1α-selective molecular glue degrader, is currently in a Phase 1a clinical study in Korea and is being developed for adenoid cystic carcinoma (ACC), castration-resistant prostate cancer (CRPC), and colorectal cancer (CRC).

We have also established PinMARS™, a proprietary E3 ligase platform built on Ligase 2, a novel E3 ligase with extremely low expression and activity in heme and immune lineage cells - distinct from commonly used ligases such as CRBN or VHL. By leveraging this heme/immune-sparing property, we aim to differentiate both our target-selection and indication strategy from conventional CRBN/VHL-based approaches. Using Ligase 2, we are currently advancing the development of an oral pan-Kras degrader as well as Ligase 2 MGD in oncology and CNS.

Txinno Bioscience is a clinical-stage biotech company headquartered in Korea, specializing in small molecules and targeted protein degraders for cancer treatment. Txinno has recently received IND approval for a Phase 2 clinical trial of TXN10128 in Korea and advanced 2nd program, TXN12923, to the preclinical stage.

Progeneer is a biotechnology company developing next-generation immunotherapies and cancer vaccines based on its proprietary TLR7/8 agonist platform, ProLNG.

ProLNG is a platform technology designed to induce potent and durable anti-tumor immune responses while improving safety and controllability. The platform has broad applicability across multiple cancer indications and therapeutic modalities.

The company's lead pipeline, ProV-001, is a personalized cancer vaccine that combines patient-specific tumor antigens with ProLNG and is being developed to prevent recurrence and induce long-term immunity in patients with B-cell lymphoma.

Progeneer has established a global intellectual property portfolio and is actively pursuing collaborations and business development opportunities with domestic and international pharmaceutical and biotechnology companies to develop innovative immunotherapies for hematologic malignancies and solid tumors. Through these efforts, the company aims to advance the global commercialization of next-generation cancer vaccine platforms and transform the paradigm of cancer treatment.

CAGE Bio is advancing novel therapies for localized treatment of immunological skin diseases. Powered by the proprietary ionic liquid platform, CAGE Bio is advancing small and large molecules including oliognucleotides that are delivered non-invasively into the skin for maximum effect site bioavailability.

Asgard Therapeutics is a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy. The company builds on ground-breaking and proprietary reprogramming technologies to develop gene therapy products designed to recreate therapeutic immune cells in vivo, setting in motion efficient and personalized immune responses. Asgard advances in vivo direct reprogramming as a next-generation cell therapy, overcoming the traditional challenges of the cell therapy field.  

Asgard Therapeutics has attracted leading investors, securing €30 million in Series A funding in 2024, following a €6 million Seed round in 2021. Its lead program, AT-108 in IND-enabling phase, is a first-in-class, off-the-shelf personalized gene therapy that directly reprograms tumor cells into a rare subset of dendritic cells.

Key proof-of-concept data on AT-108, in ex vivo (primary patient samples) and in vivo solid tumor models, were published in the peer-reviewed journal Science in 2024, demonstrating robust anti-tumor immunity in both "hot" and "cold" tumors, including monotherapy and in combination with ICB, with long-term tumor-free survival. AT-108 demonstrated a clean safety profile in a non-GLP tox study recently completed.

Asgard is seeking to raise a EUR 75M Series B to bring AT-108 towards clinical PoC.

Mustbio is a biotechnology company developing first-in-class and best-in-class tumor-selective immuno-cytokines to advance cancer immunotherapy. Our mission is to harness the power of the immune system by overcoming the limitations of conventional cytokine therapies, including narrow therapeutic windows, systemic toxicity, and limited efficacy in immunologically "cold" tumors.

Founded by experts in biologics and drug development, Mustbio is committed to delivering transformative immuno-oncology therapies for unmet medical needs.

Our proprietary STARKINE™ platform enables structure-guided cytokine engineering and computational optimization to enhance receptor selectivity, potency, and safety. By selectively activating immune cells within the tumor microenvironment while minimizing systemic exposure, STARKINE™ aims to maximize anti-tumor efficacy and improve the therapeutic index of cytokine therapies.

STARKINE™ can be applied across multiple cytokines, including IL-2 and IL-21 variants, and combined with various tumor-associated antigens (TAAs) and antibody formats to generate differentiated immunocytokines. Our BICSTA™ multispecific antibody platform further enables flexible targeting strategies for next-generation biologics.

Mustbio is advancing a pipeline of innovative immuno-oncology programs. MB4, a lead program, is a tumor-targeted aPD-1/aVEGF/IL-2v immunocytokine. In October 2025, Mustbio entered a co-development and licensing agreement with Celltrion to accelerate global development of MB4, highlighting the potential of our proprietary platforms.

Mustbio continues to expand its next-generation immunocytokine pipeline by integrating engineered cytokines with diverse targets and antibody modalities, creating new opportunities in oncology.

A clinical-stage oncology company focused on targeting GPR65 as a genetically-validated immunotherapy approach in cancer.

We are pioneering the only approach to address the fundamental causal biology of the immunologically-hostile tumor microenvironment (TME)

Vasthera is a clinical-stage pharmaceutical company developing first-in-class small-molecule therapeutics for rare and chronic diseases with high unmet needs. Our proprietary Redoxizyme™ platform generates protein oxidation modulators (POMs) designed to restore dysregulated redox signaling across multiple diseases. By targeting a central mechanism underlying oxidative stress, our approach aims to enable disease-modifying outcomes beyond symptomatic control. Our lead program VTB-10 is an oral therapy for pulmonary arterial hypertension (PAH), currently in Phase 1. With a scalable pipeline extending into neurodegeneration and oncology, Vasthera is seeking global strategic partners for out-licensing and co-development to accelerate these therapies to market.